MediPress Health-Limited Partnership

ILA 44.60As of Sun 8 Nov 2026, 12:00 UTC

TASE:MPRSHealthcare

Country Israel

PE (Fwd) •••

TSR 5Y CAGR 94.90%

Div yield —

ROE —

Medical Devices

Beta (5Y) —

PE TTM —

TSR TTM (26.77%)

Mkt cap —

ROIC —

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

ILA 52

16.34%

242.98%

Sell 2|6|8|3|9

TTM

FYE 31 Dec ILA

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

2.097

RevenueILA B

2.369

2.554

2.736

2.976

3.256

3.551

3.887

4.289

4.667

5.147

2.247

9.59%

8.79%

16.84

Revenue growth%

30.80

31.59

29.38

30.32

27.63

26.25

28.00

25.67

27.97

29.62

20.12

27.97

28.69

22.65

Gross margin%

13.14

14.37

16.61

18.95

17.21

17.55

19.43

17.66

17.03

16.92

7.56

17.55

17.12

4.76

Operating margin%

17.69

20.33

22.57

24.18

24.45

25.03

27.83

26.90

28.73

30.03

22.07

27.83

24.74

25.52

Net margin%

6.94

9.76

12.11

9.72

10.66

10.76

10.18

7.66

6.62

8.75

15.32

8.75

9.74

37.16

P/E ratio (avg)x

37.69

40.80

40.15

45.52

49.06

46.65

46.58

50.73

58.74

62.01

16.97

50.73

46.61

16.62

EV/EBITx

32.65

36.29

40.71

38.22

35.98

40.63

42.86

43.08

47.77

51.38

17.62

43.08

40.67

11.39

FCF yield (avg)%

15.27

16.39

16.32

15.61

13.54

13.49

12.85

11.04

12.37

13.76

8.30

12.85

13.65

9.35

FCF margin%

26.95

28.50

30.70

29.84

32.13

30.20

32.20

29.41

28.55

31.00

28.84

30.20

30.02

1.560

FCF / Net incomex

1.285

1.433

1.501

1.682

1.813

2.002

2.267

2.341

2.605

2.633

1.208

2.341

1.908

27.89

ROIC%

3.41

1.65

4.34

2.96

3.05

1.12

1.46

1.97

1.88

1.93

11.08

1.88

1.95

8.15

Return on equity%

6.79

8.90

11.47

14.09

12.27

15.27

13.25

16.14

13.68

15.70

26.68

15.27

13.47

9.26

Return on assets%

14.22

11.69

13.82

11.89

11.36

13.63

12.41

14.81

16.89

18.92

2.79

14.81

13.72

0.04

EPSILA

0.01

0.02

0.04

7.12%

4.97%

—

23.71

EPS growth%

10.97

12.93

12.07

11.77

10.24

7.30

8.13

6.78

7.26

7.64

16.04

7.30

9.18

0.03

Bookvalue per shILA

0.07

0.06

0.07

0.08

0.09

0.08

0.05

5.37%

1.57%

—

0.02

FCF per shareILA

0.06

0.07

0.08

0.09

0.10

0.02

4.38%

6.27%

—

0.01

Dividend per shILA

0.08

0.09

0.11

0.10

0.11

0.12

0.13

0.12

0.13

0.06

3.57%

6.24%

—

26.83

Div yield (avg)%

27.53

26.08

28.92

31.31

31.11

31.75

32.72

32.85

35.57

38.42

23.12

32.85

31.53

3.22

Payout ratio%

27.76

28.13

30.67

28.48

25.79

25.93

27.09

28.77

28.76

28.40

27.09

27.95

56.96

Shares (diluted)M

59.21

63.94

63.42

73.69

74.59

85.00

86.16

81.75

93.92

105.9

58.03

7.27%

6.58%

6.01

Buyback yield%

22.99

23.60

21.22

22.93

21.28

19.57

17.41

16.19

14.56

13.83

14.15

16.19

20.40

1.168

D/E ratiox

1.124

1.150

1.165

1.033

0.879

0.785

0.735

0.711

0.615

0.616

1.749

0.711

0.832

0.371

Enterprise valueILA B

1.389

1.276

1.256

1.217

1.229

1.147

1.140

1.183

1.243

1.068

0.585

(2.77%)

(3.31%)

0.681

LT debtILA B

1.682

1.700

1.659

1.777

1.959

1.792

1.952

2.216

2.013

2.269

2.686

2.98%

4.00%

Peers (US$2.186M)

Cap (US$)

IceCure Medical Ltd

3.157M

—

Bio-View Ltd

1.721M

—

Erech Finance Cahalach…

1.185M

—

Uscom Limited

2.144M

—

Capital

TTM

10Y

Leveragex

0.817

0.052

EBIT/Intx

0.512

0.327

0.307

Own earn%

(124.11)

104.00

67.39

Sh yield%

32.83

50.13

50.33

Owners

Insiders/Inst%

8.36

58.42

Short interest%

1.31

SBC / revenue%

2.04

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

18–30

$1 testx

—

Incr. ROIC%

MediPress Health-Limited Partnership, is a research and development life science partnership and venture capital firm specializing in seed/startups investments. The firm seeks to invest in medical research and development companies.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

ILA 5.147B

8.79%

1.00×

Cost of revenue

ILA 2.878B

9.26%

1.04×

Operating expenses

ILA 1.231B

8.16%

0.94×